Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLURE: Secukinumab 2 mL Syringe in Psoriasis
NCT02748863Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Dec 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02748863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748863.